Management Approaches That Avoid Missed Opportunities for Recovery in Schizophrenia

Management Approaches That Avoid Missed Opportunities for Recovery in Schizophrenia
1 AMA PRA Category 1 Credit(s)
Launch Date:
August 06, 2015
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:


Relevant Terms:


Christoph Correll, MD

Christoph Correll, MD
Professor of Psychiatry and Molecular Medicine, Hofstra North Shore-LIJ School of Medicine
Medical Director, Recognition and Prevention (RAP) program, Zucker Hillside Hospital
Glen Oaks, New York, USA

Christoph Correll, MD, is currently professor of psychiatry and molecular medicine at Hofstra North Shore-LIJ School of Medicine and medical director of the Recognition and Prevention (RAP) program at the Zucker Hillside Hospital in New York. He completed his medical studies at the Free University of Berlin in Germany and Dundee University Medical School in Scotland. After finishing his general psychiatry residency at the Zucker Hillside Hospital in Glen Oaks, New York, he trained in child and adolescent psychiatry at Schneider Children's Hospital in New Hyde Park, New York.
Dr. Correll's research and clinical work focus on the identification, characterization, and treatment of adults and youths with severe psychiatric disorders. His areas of expertise include the prodrome, first episode, multi-episode, and refractory illness phase of severe psychotic and mood disorders, including schizophrenia, bipolar disorder, and major depression, as well as aggressive spectrum disorders. He further focuses on the risk–benefit evaluation of psychotropic medications, including the extent and mechanisms of cardiometabolic and neuromotor adverse effects.
Dr. Correll has authored or co-authored more than 300 journal articles and has served on several expert consensus panels on the use of antipsychotics across a range of psychiatric disorders. He is a reviewer for more than 70 peer-reviewed journals and an editorial board member of 11 scientific journals. Dr. Correll is the Principal Investigator or Steering Committee member of several large, federally funded grants. He has received more than 30 national and international research awards and fellowships for his work, and he was listed in 2014 by Thompson Reuters as one of "the most influential scientific minds" and top 1% cited scientists in the area of psychiatry.

Peter Haddad, MD, FRCPsych

​Peter Haddad, MD, FRCPsych 
Consultant, Community Psychiatry, Greater Manchester West Mental Health NHS Foundation Trust
Honorary Reader, University of Manchester
Salford, Greater Manchester, United Kingdom

Peter Haddad MD, FRCPsych, is a consultant in community psychiatry in Salford, United Kingdom, where he works with a community mental health team. He also provides psychiatric input to a Bail Hostel in a project run by the Probation Service and is an honorary reader at the University of Manchester. His clinical and research interests focus on the treatment of affective disorders and schizophrenia. He also has a major interest in teaching, including public education and combatting the stigma associated with mental health problems. He has contributed to several evidence-based treatment guidelines, including the British Association for Psychopharmacology guidelines for depression (2008), bipolar disorder (2009), and schizophrenia (2011). He was a member of the Guideline Development Group for the National Institute for Health and Care Excellence's guidelines for bipolar disorder (2006) and medicines adherence (2009). He is joint editor of a textbook on antipsychotic long-acting Injections and a textbook on adverse syndromes and psychiatric drugs (both published by Oxford University Press).

Peter J. Weiden, MD

Peter J. Weiden, MD
Professor of Psychiatry, University of Illinois Medical Center
Research Psychiatrist, Uptown Research Institute
Chicago, Illinois

Peter J. Weiden, MD, is professor of psychiatry at the University of Illinois Medical Center in Chicago. He is a research psychiatrist at Uptown Research Institute, a clinical trials program specializing in new therapies for severe mental illness.
Dr. Weiden's career has focused on improving clinical outcomes for patients with schizophrenia. His research centers on bridging psychopharmacology and public health issues in the treatment of schizophrenia, and he has a particular interest in pharmacologic and psychosocial interventions to help patients and clinicians address medication adherence barriers.
Dr. Weiden earned his BA in chemistry from Swarthmore College in Pennsylvania and his MD from the State University of New York at Stony Brook. He completed his psychiatric residency at the Payne Whitney Clinic–New York Hospital and a psychiatric epidemiology fellowship at the Mailman School of Public Health at Columbia University.
1. Integrate evidence-based medical and non-medical interventions for improved schizophrenia treatment adherence into daily practice in order to promote recovery
2. Evaluate and interpret efficacy, safety, and outcomes data for long-acting injectable (LAI) antipsychotics for schizophrenia
3. Select the most appropriate patients for LAI intervention
4. Institute discussions with patients that include incorporating LAIs as a potential management option

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and RMEI, LLC. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The University of Cincinnati designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

According to the disclosure policy of the University of Cincinnati College of Medicine, all faculty, planning committee members, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interest related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. Disclosure will be made at the time of activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
  • Christoph Correll, MD, has affiliations with Actavis, AbbVie, Genentech, Intra-Cellular Therapies, Lundbeck, Otsuka, Reviva, Roche, Sunovion, Supernus (Advisory Board, Consultant); Gerson Lehrman Group, Janssen/Johnson & Johnson, MedAvante, Medscape, Pfizer, ProPhase, Takeda (Consultant); Otsuka, Lundbeck, Takeda (Research Support).
  • Peter Haddad, MD, FRCPsych, has affiliations with Eli Lilly, Janssen-Cilag, Lundbeck, Otsuka, Quantum Pharmaceuticals, Sunovion (Advisory Board); Eli Lilly, Janssen, Lundbeck, Otsuka, (Board Member).
  • Peter J. Weiden, MD, has affiliations with Alkermes, Delpor, Forum, Johnson & Johnson (Janssen Pharmaceuticals), Lundbeck, Otsuka, Novartis, Teva, Vanda (Consultant); AbbVie, Alkermes, Forum, Forest Laboratories, Genentech, Johnson & Johnson (Janssen Pharmaceuticals), Neurocrine Biosciences, Otsuka, Reckitt Benckiser Pharmaceuticals, Takeda (Research Support); Forum, Jazz, Johnson & Johnson (Janssen Pharmaceuticals), Lundbeck, Otsuka, Novartis, Sunovion.
University of Cincinnati
  • Susan P. Tyler, MEd, CMP, CHCP, CME Director, has no affiliations with commercial interests relative to the content to disclose.
  • Rick Ricer, MD, CME Physician Reviewer, has no affiliations with commercial interests relative to the content to disclose.
  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests relative to the content to disclose.
  • Boris Rozenfeld, MD, has no affiliations with commercial interests to disclose.
  • Amy Reeve has no affiliations with commercial interests relative to the content to disclose.
The opinions expressed during the enduring activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees’ professional development.
Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.
Estimated time to complete: 1.0 hour
Medium: Internet

There is no fee for this educational activity.

This activity is supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.

By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive up to 1.0 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
Physicians who successfully complete the post-test and evaluation will receive CME credit. Users must score 70% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.